Review article
Propranolol therapy for infantile haemangiomas: Review of the literature

https://doi.org/10.1016/j.ijporl.2010.01.001Get rights and content

Abstract

Objectives

Haemangiomas are the most common tumors of infancy affecting approximately 1 in 10 children. Unlike other tumors, haemangiomas enter an involution phase, during which they usually regress over the next several months to years. Sometimes intervention is required due to proliferative growth which is complicated by ulceration, bleeding, persistent aesthetic deformity or infection.

Methods

Review of the literature.

Results

Propranolol, a nonselective beta-blocker, has recently been introduced as a novel modality for the treatment of proliferating haemangiomas. The exact mechanism of action of propranolol in the treatment of haemangiomas remains unclear, but vasoconstriction, down-regulation of angiogenic factors such as VEGF and bFGF and up-regulation of apoptosis of capillary endothelial cells may be responsible for the reduction of haemangiomas. Besides, an inhibition of MMP-9 and HBMEC expression by propanolol is discussed as possible mechanism influencing the growth of haemangiomas. However, there are different case reports of successfully treated infants in the current literature.

Conclusion

There is the obtain that propranolol will detach steroids in the therapy for infantile haemangiomas.

Introduction

Haemangiomas are the most common tumors of infancy affecting approximately 1 in 10 children [1]. Haemangiomas are more common in Caucasians, being evident in up to 12% of all children and occurring more frequently in females than in males, in a ratio of 3:1. Sixty per cent of haemangiomas are located in the head and neck area, whereas 25% occur on the trunk and 15% on the extremities [2]. Usually 80% of all haemangiomas are single lesions, but 20% of affected infants develop multiple tumors. Infantile haemangiomas are characterized by an inconspicuous appearance at birth, but undergo rapid and intermittent growth throughout the first year of life. By the age of 5 years usually 50% of the lesions have involuted. This increases to nearly 70% by the age of 7 years and about 90% by the age of 9 years. Nevertheless, in 40–50% of all affected children teleangiectatic cutaneous vessels, fibrous-fatty tissue or scar formations can be observed as a residue of the lesions [3], [4].

Although general outlines of haemangioma growth characteristics have long been recognized, specific details about haemangima growth and information regarding differences in growth patterns between haemangioma subtypes are lacking. There are different theories on the origin of infantile haemangiomas. These include suggestions of placental origin, intrinsic defect or somatic endothelial mutation, and extrinsic factors creating a conductive milieu for growth. However, no current hypothesis explains all the characteristics of infantile haemangiomas. In the last several years, much has been learned about molecular features of haemangioma and haemangioma-derived endothelial cells cultured in vitro. Haemangioma endothelial cells exhibit constitutive vascular endothelial growth factor signalling the endothelial cells comprising infantile haemangiomas show intense and persistent immunoreactivity for a number of tissue-specific markers that is highly characteristic of placental microvasculature like GLUT-1. Therefore there is the hypothesis that haemangiomas possibly stem from placental tissue or resemble it [3], [4]. Infantile haemangiomas vary tremendously from small, benign growth to large, function-threatening tumors. Most require no treatment, but treatment is needed if dramatic aesthetic, and/or functional impairment as visual or airway obstruction or ulceration arises [5]. Until now oral corticosteroids are considered as first-line therapy for such troublesome and severe haemangiomas. Systemic steroids have proven effectiveness, but the risks of long-term and high dose use include growth disturbances and immune system dysfunction as well as ulcerations up to severe tissue loss. Moreover, there are cases of fast growing infantile haemangiomas which show no response to steroid therapy. Other therapeutic options as interferon alpha and vincristine are used less often because of side effects and toxicity [6]. In cases of life-threatening haemangiomas and haemangiomatosis cyclophosphamide was also reported to offer promising results [7]. However, the serious side effects of cyclophosphamide like avascular necrosis, cardiomyopathy, pulmonary fibrosis, gonadal damage, and subsequent malignancies [8] have to be kept in mind and therefore the application of cyclophosphamide in the therapy of infantile haemangiomas needs to be carefully considered. Reported successful invasive treatments, especially for airway haemangiomas, include intralesional steroid injection, endoscopic and open excision, laser therapy, and tracheotomy. The treatment plan depends on many factors, including the size and extent of the lesion, social situations, and surgeon's comfort or experience with any given treatment modality.

The use of propranolol in the treatment of haemangiomas was serendipitously discovered last year in 2 children who showed rapid regression of disease when treated for cardiopulmonary conditions [9]. The treatment course occurred during the proliferative phase of growth, but the impact of propranolol on persistent disease remains unknown. After this notification [9] several groups worldwide initiated propranolol therapy in children with haemangiomas and gained experiences with this treatment. Therefore it was necessary to summarize the results. This review presents the current knowledge on propranolol therapy in infantile haemangiomas and the assumptions regarding the possible mechanism of propanolol in haemangioma therapy.

Section snippets

Propranolol for haemangiomas—mode of action and side effects

Propranolol was the first clinically useful beta adrenergic receptor antagonist. Invented by Sir James W. Black, it revolutionized the medical management of angina pectoris and is considered to be one of the most important contributions to clinical medicine and pharmacology of the 20th century [10]. Beta-blockers may also be referred to as beta-adrenergic blocking agents, beta-adrenergic antagonists, or beta antagonists.

Propranolol is a nonselective beta-blocker. The levorotatory isomer of

Review of case reports (Table 1)

Léauté-Labrèze et al. [9] treated a child with propranolol at a dose of 3 mg/kg of body weight per day because of its obstructive hypertrophic myocardiopathy. Simultaneously the child had a nasal haemangioma. This showed a coincidental impressive improvement during this therapy. A second child with pathological cardiac findings and a facial haemangioma was treated with propranolol at a dose of 2 mg/kg of body weight per day and showed a clear resolution of the haemangioma. Because of this

Conclusion

The recent report of dramatic response of haemangiomas to propranolol was initially a discovery by chance in patients who had cutaneous lesions associated with cardiac disease [9]. All reported cases of cutaneous, subglottic and oropharyngeal haemangiomas demonstrate a significant regression after the therapy with propranolol/beta-blockers without any relevant side effects. In all cases the therapy with propranolol showed a prompt effect also after ineffective therapy with systemic steroids or

References (23)

  • C. Léauté-Labrèze et al.

    Efficacy of beta-blockers in infantile haemangiomas: the physiopathological significance and therapeutic consequences

    Ann. Dermatol. Venerol.

    (2008)
  • L.C. Chang et al.

    Growth characteristics of infantile hemangiomas: implications for management

    Pediatrics

    (2008)
  • B. Eivazi et al.

    Update on haemangiomas and vascular malformations of the head and neck

    Eur. Arch. Otorhinolaryngol.

    (2009)
  • J.A. Werner et al.

    Optimal treatment of vascular birthmarks

    Am. J. Clin. Dermatol.

    (2003)
  • L. Buckmiller et al.

    Propranolol for airway hemangiomas: case report of novel treatment

    Laryngoscope

    (2009)
  • J. Nguyen et al.

    Pharmacological therapy for periocular infantile haemangiomas: a review of the literature

    Semin. Othalmol.

    (2009)
  • A. Vlahovic et al.

    Diffuse neonatal hemangiomatosis treatment with cyclophosphamide: a case report

    J. Pediatr. Hematol. Oncol.

    (2009)
  • S. Gottschling et al.

    Two infants with life-threatening diffuse neonatal hemangiomatosis treated with cyclophosphamide

    Pediatr. Blood Cancer

    (2006)
  • C. Léauté-Labrèze et al.

    Propranolol for severe haemangiomas of infancy

    N. Engl. J. Med.

    (2008)
  • M. Helfand et al.

    Drug Class Review on Beta Adrenergic Blockers

    (2007)
  • E.C. Siegfried et al.

    More on propranolol for haemangiomas of infancy

    N. Engl. J. Med.

    (2008)
  • Cited by (137)

    • A study on the recent developments in voltammetric sensors for the β-blocker propranolol hydrochloride

      2022, Biomedical Engineering Applications for People with Disabilities and the Elderly in the COVID-19 Pandemic and Beyond
    • Printing of cutaneous patches loaded with propranolol for the treatment of infantile haemangiomas

      2021, Journal of Drug Delivery Science and Technology
      Citation Excerpt :

      IH are classified by their morphology into superficial, subcutaneous (deep), and mixed haemangiomas [1]. If not appropriately treated, most of them cause disfigurements or functional impairments (e.g., obstruction of airways and vision, cardiac insufficiency, and hypothyroidism) [1,2]. PR clinical efficacy was firstly documented in 2008 when Léautè-Labréze and co-workers observed a rapid regression of IH in a patient who received the β-blocker for the treatment of a pre-existent cardiovascular disease [3].

    • Enhanced skin delivery of propranolol HCl using nonionic surfactant-based vesicles for topical treatment of infantile hemangioma

      2021, Journal of Drug Delivery Science and Technology
      Citation Excerpt :

      Infantile hemangiomas (IHs) are frequent neoplasms that consist of proliferating endothelial-like cells [1,2]. It affects approximately 1 in 10 children [3]. They are more common in Caucasian populations and in female infants [4].

    • Giant hemangioma involving the tongue: A surgical strategy to improve quality of life

      2020, Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
      Citation Excerpt :

      Radiotherapy has been described as therapeutic option, especially for intraosseous hemangiomas. Nevertheless, its adverse effects, such as damage to the normal adjacent tissue growth, residual scarring and malignancy, are well-know and are not justified for benign conditions like hemangiomas and vascular malformations [8]. The most critical complication of macroglossia is airway compromise, but other associated morbidities, including issues regarding speech function, feeding and cosmesis might warrant a surgical solution.

    • Middle ear capillary haemangioma: Review of literature and appraisal of management options

      2016, Auris Nasus Larynx
      Citation Excerpt :

      The pathophysiology of haemangioma development is described with three identifiable stages: Spontaneous regression of infantile capillary haemangiomas occurs in approximately 50% of children by the age of 5 years and 90% by the age of 9 years [4,5]. The rate of regression in older children is less well understood but thought to be rare [5].

    View all citing articles on Scopus
    View full text